WARD (WARD) fluctuated by 144.3% in 24 hours: Highly speculative volatility with surging trading volume
Bitget Pulse2026/04/26 16:02Volatility Brief
In the past 24 hours, the price of WARD rebounded from a low of $0.00221 (Coingecko data: $0.002356) to a high of $0.0054 (CMC data: $0.005198), with the current price quoted around $0.00305 (CMC: $0.002703, Coingecko: $0.00308), registering an amplitude of 144.3% and an overall increase of approximately 13.8%-19.68%. The 24-hour trading volume surged significantly to between $1.53 million (Coingecko) and $3.35 million (CMC), far exceeding the market cap of around $700,000, indicating high speculative activity.
Summary of Reasons for Abnormal Movements
• No official announcements, listings, or partnership events have been identified in the past 24 hours.
• No public reports of large-scale whale transactions or unusual on-chain activity have been found.
• Trading signals on platform X show that some AI tools (such as Finora AI) issued bullish signals on the evening of April 25, targeting $0.002927-$0.003774, accompanied by an increase in trading volume.
Market Opinions and Outlook
Community sentiment is mainly negative, with many users accusing the project of potential “rug pull” or liquidity removal. There are disputes concerning Discord bans and rewards directed at the @wardenprotocol team; a minority view it as a potential low market cap opportunity. No mainstream analysts have published predictions. Risk Warning: Low liquidity may amplify volatility; beware of speculative manipulation.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring. It is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.